联环药业：获得盐酸利多卡因凝胶《药品注册证书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Lidocaine Hydrochloride Gel, which is expected to enhance its product line and competitiveness, although it is not anticipated to have a significant impact on recent performance [1] Group 1: Product Approval - The product is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] - The registered specification of the drug is 2% (10g:0.2g) [1] Group 2: Financial Implications - Cumulative R&D investment in this project amounts to approximately 7.27 million yuan [1] - The estimated sales revenue for this product in secondary and higher-level hospitals across the country in 2024 is approximately 40.86 million yuan [1] Group 3: Strategic Impact - The approval of this product is expected to enrich the company's product line and enhance its competitive position in the market [1] - The company anticipates no major impact on its recent performance following this approval [1]